ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025
Risk Stratification and Prognosis Determination Based on Protein Lysine Crotonylation in Patients with Resected Pancreatic Cancer: A Multicenter Study.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeDespite advances in neoadjuvant therapy and surgery, a limited increase in the 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) has occurred, implying the importance of postoperative management. This study aims to achieve risk stratification of patients with PDAC, providing guidance for clinicians to make better regimen choices and realizing precision treatment. EXPERIMENTAL
designFive protein posttranslational modifications (PTM) were detected to find out the most prognostic marker using the IHC method. The predictive and prognostic performance of lysine pan-crotonylation (pan-Kcr) expression standing out from the initial selection was measured in the discovery cohort and validated in two independent cohorts. A risk stratification model was constructed based on pan-Kcr expression.
resultsA total of 309 (93, 114, and 102 from Qingdao, Tianjin, and Jilin cohorts, respectively) patients with PDAC were included. Pan-Kcr expression was the only significantly deregulated PTM between cancer and its paracancerous tissues. The low pan-Kcr level was an independent predictive (HR, 0.470; P = 0.0090) and prognostic (HR, 0.312; P < 0.0001) marker for patients with PDAC. We constructed a risk-stratification model based on pan-Kcr expression, and high-risk patients suffered a significantly shorter disease-free survival and overall survival (median disease-free survival, 5 vs. 12.5; P < 0.0001; median overall survival, 7 vs. 24; P < 0.0001). The model was well validated in two independent cohorts.
conclusionsPan-Kcr is an independent predictive and prognostic marker for resected patients with PDAC. The risk stratification could provide guidance for clinicians to make precision regimen choices. Also, our findings illustrated the feasibility of PTM-guided prognosis and biomarker-aided PDAC adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.